Assoc. Prof. Dr. Yuchun Wei | Oncology | Best Researcher Award

Shandong Cancer Hospital | China

Dr. Yuchun Wei is a distinguished oncology researcher and radiotherapy physician at Shandong Cancer Hospital, China. Her work focuses on developing new imaging biomarkers for cancer detection, biological characterization, staging, and individualized therapy planning. With a deep commitment to advancing medical imaging, Dr. Wei’s research explores innovative imaging methods to improve cancer diagnostics and treatment.

Professional profile👤

Scopus

Strengths for the Awards✨

• 🌟 Exceptional Research Contributions: Dr. Wei has an impressive record of high-impact publications in prestigious journals like Radiology (IF=19.7), J Nucl Med (IF=11.082), and Eur J Nucl Med Mol Imaging (IF=10.057), reflecting the quality and significance of her work.

• 🔬 Pioneering Work in Imaging Biomarkers: Her research focuses on developing new imaging methods for cancer detection, prognosis, and treatment monitoring, demonstrating innovation and addressing critical needs in oncology.

• 📈 Leadership Roles: Experience as Deputy Director and Assistant Director at Shandong Cancer Hospital highlights her leadership in clinical and research settings.

• 👩‍🏫 Collaborative Impact: Contributions as a corresponding and co-corresponding author in multiple papers underscore her role in guiding research teams.

• 🏆 Recognition of Excellence: Consistent publication in top-tier journals (Q1) across diverse aspects of nuclear medicine and oncology points to widespread recognition in her field.

🎓 Education

• Ph.D. in Oncology (2018.09-2022.06) – Shandong University, under the mentorship of Jinming Yu (Academician of Chinese Academy of Engineering).
• Master’s in Oncology (2013.09-2016.06) – Jinan University, mentored by Shuanghu Yuan.
• Bachelor’s in Traditional Chinese and Western Medicine Clinical (2007.09-2012.06) – Shandong University of Traditional Chinese Medicine.

💼 Experience

• 🔺 Deputy Director (2021.09-2022.08) – MDT Quality Management Office, Shandong Cancer Hospital.
• Radiotherapy Physician (2017.07-Present) – Shandong Cancer Hospital.
• Assistant Director (2020.12-2021.08) – Radioimmunity and Molecular Imaging Room, Shandong Cancer Hospital.

🔮 Research Interests On Oncology

Dr. Wei’s research delves into new imaging techniques for cancer detection and treatment evaluation. Her primary focus is on developing prognostic and predictive imaging biomarkers, enhancing individualized therapy planning, and monitoring cancer progression.

🏆 Awards

• Recognition for contributions to cancer imaging and personalized therapy at Shandong Cancer Hospital.

📝 Publications

• Title: FAPI Compared with FDG PET/CT for Diagnosis of Primary and Metastatic Lung Cancer
  Authors: Wei Yuchun#, Ma Li, Li Pei, Lu Jie, Ren Jiazhong, Yan Shoumei, Wu Hongbo, Yuan Shuanghu, Fu Zheng, Yu Jinming
  Year: 2023
  Citations: Radiology, 308(2):e222785. (JCR Q1, IF=19.7)

• Title: [18F]AlF-NOTA-FAPI-04 PET/CT for Predicting Pathologic Response of Resectable Esophageal Squamous Cell Carcinoma to Neoadjuvant Camrelizumab and Chemotherapy: A Phase II Clinical Trial
  Authors: Yinjun Dong#, Zhendan Wang#, Xinying Hu, Yuhong Sun, Jingjie Qin, Qiming Qin, Shuguang Liu, Shuanghu Yuan, Jinming Yu, Yuchun Wei* (Corresponding author)
  Year: 2024
  Citations: J Nucl Med. (JCR Q1, IF=9.1)

• Title: Early Detection of Radiation-Induced Myocardial Damage by [18F]AlF-NOTA-FAPI-04 PET/CT Imaging
  Authors: Wei Yuchun#, Sun Y, Liu J, Zhang G, Qin X, Xu S, Wang S, Tao Y, Pei J, Yu J
  Year: 2023
  Citations: Eur J Nucl Med Mol Imaging, 50(2):453-464. (JCR Q1, IF=10.057)

• Title: Response Prediction Using 18F-FAPI-04 PET/CT in Patients with Esophageal Squamous Cell Carcinoma Treated with Concurrent Chemoradiotherapy
  Authors: Hu X, Zhou T, Ren J, Duan J, Wu H, Liu X, Mu Z, Liu N, Wei Yuchun* (Co-corresponding author), Yuan ST*
  Year: 2023
  Citations: J Nucl Med, 64(4):625-631. (JCR Q1, IF=11.082)

• Title: [18F]AlF‑NOTA‑FAPI‑04: FAP‑targeting Specificity, Biodistribution, and PET/CT Imaging of Various Cancers
  Authors: Wei Yuchun#, Zheng Jinsong, Ma Li, Liu Xiaoli, Xu Shengnan, Wang Shijie, Pei Jinli, Cheng Kai, Yuan Shuanghu, Yu Jinming
  Year: 2022
  Citations: Eur J Nucl Med Mol Imaging, 49(8):2761-2773. (JCR Q1, IF=10.057)

• Title: [18F]AlF‑NOTA‑FAPI‑04 PET/CT Uptake in Metastatic Lesions on PET/CT Imaging Might Distinguish Different Pathological Types of Lung Cancer
  Authors: Wei Yuchun#, Cheng Kai#, Fu Zheng, Zheng Jinsong, Mu Zhengshuai, Zhao Chenglong, Liu Xiaoli, Wang Shijie, Yu Jinming, Yuan Shuanghu
  Year: 2022
  Citations: Eur J Nucl Med Mol Imaging, 49(5):1671-1681. (JCR Q1, IF=10.057)

• Title: Tumor Angiogenesis at Baseline Identified by 18F-Alfatide II PET/CT May Predict Survival Among Patients with Locally Advanced Non-Small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy
  Authors: Wei Yuchun#, Qin Xueting, Liu Xiaoli, Zheng Jinsong, Luan Xiaohui, Zhou Yue, Yu Jinming, Yuan Shuanghu
  Year: 2022
  Citations: J Transl Med, 20(1):63-72. (JCR Q2, IF=8.44)

• Title: Value of [18F]AlF‑NOTA‑FAPI‑04 PET/CT for Differential Diagnosis of Malignant and Various Inflammatory Lung Lesions: Comparison with [18F]FDG PET/CT
  Authors: Kailin Qiao, Xueting Qin, Shuai Fu, Jiazhong Ren, Jing Jia, Xinying Hu, Yuanyuan Tao, Shuanghu Yuan, Yuchun Wei (Corresponding author)
  Year: 2023
  Citations: Eur Radiol. (JCR Q1, IF=5.9)

• Title: Stereotactic Comparison Study of 18F-Alfatide and 18F-FDG PET Imaging in an LLC Tumor-Bearing C57BL/6 Mouse
  Authors: Wei Yuchun# et al.
  Year: 2016
  Citations: Sci Rep, 6:28757. (JCR Q1, IF=5.228)

• Title: Diagnostic Value of 18F-NOTA-FAPI PET/CT in a Rat Model of Radiation-Induced Lung Damage
  Authors: Xueting Qin, Shijie Wang, Xiaoli Liu, Jinghao Duan, Kai Cheng, Zhengshuai Mu, Jing Jia, Yuchun Wei (Co-corresponding author), Shuanghu Yuan
  Year: 2022
  Citations: Front Oncol, 12:879281. (JCR Q2, IF=5.738)

📅 Conclusion

Dr. Yuchun Wei is a leading figure in oncology and molecular imaging, dedicated to developing cutting-edge imaging techniques to revolutionize cancer diagnosis and treatment. Her contributions have significantly advanced the field of individualized cancer therapy, making her a standout candidate for this award.